Efficacy of 25% Trichloroacetic Acid Peel Versus 30% Salicylic Acid Peel in Mild to Moderate Acne Vulgaris

Sponsor

Combined Military Hospital Abbottabad (Other)

Overall Status

Completed

CT.gov ID

NCT05712837

Collaborator

(none)

Enrollment

Location

Arms

Actual Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To compare the efficacy of 25% trichloroacetic acid peel versus 30% salicylic acid peel in mild to moderate acne vulgaris.

Study Design: Randomized Control Trial. Place And Duration of Study: Department of Dermatology, CMH Abbottabad from 01 Jun 2022 to 30th Nov, 2022.

Methodology: A total of 60 patients presented with mild or moderate acne vulgaris were randomized into two groups comprising 30 patients in each group and treated with either the TCA peel or the SA peel at 2-week intervals for 12 weeks. Patients in Group A were treated with 25% TCA peel whereas patients in Group B were treated with 30% SA peel. At the end of therapy after 12 weeks, evaluation of active acne was done by individual lesion counts (comedones, papules and pustules) and calculation of the Michaelsson acne score (MAS).

Condition or Disease	Intervention/Treatment	Phase
Acne Vulgaris	Drug: 25% TRICHLOROACETIC ACID Drug: 30% salicylic acid	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

60 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Efficacy of 25% Trichloroacetic Acid Peel Versus 30% Salicylic Acid Peel in Mild to Moderate Acne Vulgaris

Actual Study Start Date :

Jun 1, 2022

Actual Primary Completion Date :

Nov 30, 2022

Actual Study Completion Date :

Nov 30, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Group A 25% TCA 25% TCA peel Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.	Drug: 25% TRICHLOROACETIC ACID Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment. Other Names: Peeling agent
Active Comparator: Group B 30% SALICYLIC ACID 30% SA peels Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment	Drug: 30% salicylic acid Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment Other Names: Peeling agent

Arm

Intervention/Treatment

Active Comparator: Group A 25% TCA

25% TCA peel Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.

Drug: 25% TRICHLOROACETIC ACID

Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.

Other Names:

Peeling agent

Active Comparator: Group B 30% SALICYLIC ACID

30% SA peels Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment

Drug: 30% salicylic acid

Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment

Other Names:

Peeling agent

Outcome Measures

Primary Outcome Measures

Effectiveness of 25 % trichloroacetic acid peel versus 30 % salicylic acid peel in the treatment of mild to moderate acne vulgaris [12 weeks]
Michaelson acne scores (MAS) Michaelson acne scores (MAS) was used to measure the effectiveness of both peels

Eligibility Criteria

Criteria

Ages Eligible for Study:

13 Years to 22 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Patients with mild or moderate facial acne vulgaris presented in dermatology opd

Exclusion Criteria:

Patients with grade III or IV acne vulgaris
patients taking any acne medications or had taken oral or topical medications in the past 4 weeks
pregnant female patients or nursing a baby
patients with known hypersensitivity to the formulations used in the study or a history of photosensitivity
hypertrophic scars, keloidal tendency, active or recurrent herpes simplex infection
active dermatosis
unrealistic expectations

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cmh abbottabad	Abbottābād	Kpk	Pakistan	22010

Sponsors and Collaborators

Combined Military Hospital Abbottabad

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Dr kiran gul, principal investigator, Combined Military Hospital Abbottabad

ClinicalTrials.gov Identifier:

NCT05712837

Other Study ID Numbers:

CMHAtd-ETH-15-Derm-22

First Posted:

Feb 6, 2023

Last Update Posted:

Feb 6, 2023

Last Verified:

Jan 1, 2023

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Acne Vulgaris

Salicylic Acid

Salicylates

Study Results

No Results Posted as of Feb 6, 2023